title: Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
abstract: Th17 cells represent a distinct subset of CD4 effector T cells with potent pathogenic qualities, capable of directly mediating tumor cell destruction. IL-2 has frequently been shown to have a negative effect on Th17 differentiation while supporting regulatory T-cell (FoxP3CD4, TREG) growth and development in both in vitro models and in vivo animal models. We investigated the effect of in vivo IL-2 on both the Th17 and FoxP3CD4 T-cell compartments in a human model of cancer. High-dose IL-2 (HDIL-2) was administered at a dose of 720,000 IU/kg to patients with melanoma (n=7) and peripheral blood was collected at baseline and at 24, 48, 72, and 96 hours posttreatment. Peripheral blood mononuclear cells (PBMCs) were isolated and subjected to intracellular cytokine and extracellular receptor staining for flow cytometry. We report that HDIL-2 increased both frequencies and absolute numbers of Th17 cells on day 4 of treatment. The administration of HDIL-2 to patients with melanoma increased IL-6 production by peripheral immune cells, a cytokine vital in the downregulation of FoxP3 expression and expansion of the Th17-cell population. Furthermore, we demonstrated that FoxP3CD4 T cells express IL-17 in patients with melanoma undergoing HDIL-2 therapy. Taken together, our findings indicate that HDIL-2 combined with the conditions of malignancy create an immune environment supportive of Th17 differentiation and that expansion of this compartment may occur through the transdifferentiation of IL-17-secreting FoxP3CD4 T cells.
authors.affiliation: Departments of *Surgery †Hematology and Medical Oncology ‡Surgical Oncology, Winship Cancer Institute §Emory Transplant Center, Emory University, Atlanta, GA.
authors.forename: Maggie L
authors.initials: ML
authors.lastname: Diller
authors.forename: Ragini R
authors.initials: RR
authors.lastname: Kudchadkar
authors.forename: Keith A
authors.initials: KA
authors.lastname: Delman
authors.forename: David H
authors.initials: DH
authors.lastname: Lawson
authors.forename: Mandy L
authors.initials: ML
authors.lastname: Ford
mesh_terms: D002454:Cell Differentiation; D049109:Cell Proliferation; D054338:Cell Transdifferentiation; D002478:Cells, Cultured; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods*; D020381:Interleukin-17 / Q000378:metabolism; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*; D000098546:Interleukin-21
chemical_list: C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D020381:Interleukin-17; D007376:Interleukin-2; D015850:Interleukin-6; D007378:Interleukins; D000098546:Interleukin-21